EUVIMEDEUVIMED entdecken
Crossref

HSP 90‐Alpha and Serotransferrin as Potential Biomarkers for Predicting IL ‐17 Inhibitor Response in Non‐Radiographic Axial Spondyloarthritis: A Retrospective Analysis

Linkai Fang, Xubin Hao iD, Chiduo Xu, Xianghui Wen iD, Xinyu Wu, Xuqi Zheng iD, Dong Liu, Liudan Tu, Zetao Liao, Mingcan Yang, Ya Xie, Yanli Zhang und 2 weitere

International Journal of Rheumatic Diseases · 2025

DOI: 10.1111/1756-185x.70303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Linkai Fang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Interleukin-17, HSP90 Heat-Shock Proteins, Antibodies, Monoclonal, Humanized, Axial Spondyloarthritis. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Science and Technology Planning Project of Guangdong Province, Guangdong Clinical Research Center of Immune disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐radiographic axial spondyloarthritis (nr‐axSpA) is an early stage of axial spondyloarthritis characterized by the absence of definitive radiographic changes. Interleukin‐17 inhibitors (IL‐17i) have shown efficacy in treating nr‐axSpA, but a significant proportion of patients fail to respond. Identifying predictive biomarkers for IL‐17i response is crucial for optimizing treatment strategies.

Methods

This retrospective study analyzed pre‐treatment serum samples from nr‐axSpA patients treated with secukinumab. Responders (R) and non‐responders (NR) were defined based on changes in ASDAS‐CRP scores after 12 weeks of therapy. Serum protein profiles were analyzed using liquid chromatography–tandem mass spectrometry (LC–MS/MS) with label‐free quantification, followed by validation of candidate proteins using enzyme‐linked immunosorbent assay (ELISA). Statistical analyses included Student's t ‐test, Mann–Whitney U ‐test, and Spearman's correlation.

Results

LC–MS/MS identified 47 differentially expressed proteins (DEPs) between R and NR groups, with 31 upregulated and 16 downregulated in NR. Seven proteins including heat shock protein HSP 90‐alpha (HSP90α) and serotransferrin were selected for ELISA validation. ELISA confirmed significantly higher HSP90α ( p = 0.027) and lower serotransferrin ( p = 0.034) levels in NR compared to R. HSP90α showed a mild negative correlation with the reduction of BASDAI scores ( r = −0.30, p = 0.035), while serotransferrin exhibited a mild positive correlation ( r = 0.287, p = 0.048). Both proteins correlate mildly with the disease activity index.

Conclusion

Serum levels of HSP90α and serotransferrin may serve as potential biomarkers for predicting IL‐17i treatment response in nr‐axSpA patients. Elevated HSP90α and reduced serotransferrin levels may reflect chronic inflammation and disease activity, particularly from a subjective symptom perspective. Further validation in prospective studies is needed to confirm their utility in guiding personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-17HSP90 Heat-Shock ProteinsAntibodies, Monoclonal, HumanizedAxial SpondyloarthritisConalbuminTransferrinHumansBiomarkersRetrospective StudiesMaleFemaleAdultTreatment OutcomeMiddle AgedPredictive Value of TestsTandem Mass Spectrometry

Stichwörter der Autor:innen

ELISAHSP90αIL‐17 inhibitorsLC–MS/MSbiomarkersnon‐radiographic axial spondyloarthritisserotransferrin

Substanzen

BiomarkersInterleukin-17HSP90 Heat-Shock ProteinsAntibodies, Monoclonal, HumanizedConalbuminsecukinumabTransferrin

Autor:innen und Institutionen

  • Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Shenzhen Longhua Institute of Immunology Transformation, Shenzhen, China.
  • Department of Rheumatology, Shenzhen Longhua District Central Hospital, Shenzhen, China.

ORCID-Profile: Xubin Hao, Xianghui Wen, Xuqi Zheng

Förderung

  • Science and Technology Planning Project of Guangdong Province
  • Guangdong Clinical Research Center of Immune disease

Zitieren

APA

Fang, L., Hao, X., Xu, C., Wen, X., Wu, X., Zheng, X., Liu, D., Tu, L., Liao, Z., Yang, M., Xie, Y., Zhang, Y., Chen, S., & Gu, J. (2025). HSP 90‐Alpha and Serotransferrin as Potential Biomarkers for Predicting IL ‐17 Inhibitor Response in Non‐Radiographic Axial Spondyloarthritis: A Retrospective Analysis. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70303

Vancouver

Fang L, Hao X, Xu C, Wen X, Wu X, Zheng X, et al. HSP 90‐Alpha and Serotransferrin as Potential Biomarkers for Predicting IL ‐17 Inhibitor Response in Non‐Radiographic Axial Spondyloarthritis: A Retrospective Analysis. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70303

BibTeX
@article{Fang2025,
  author = {Fang, Linkai and Hao, Xubin and Xu, Chiduo and Wen, Xianghui and Wu, Xinyu and Zheng, Xuqi and Liu, Dong and Tu, Liudan and Liao, Zetao and Yang, Mingcan and Xie, Ya and Zhang, Yanli and Chen, Shude and Gu, Jieruo},
  title = {HSP 90‐Alpha and Serotransferrin as Potential Biomarkers for Predicting IL ‐17 Inhibitor Response in Non‐Radiographic Axial Spondyloarthritis: A Retrospective Analysis},
  journal = {International Journal of Rheumatic Diseases},
  year = {2025},
  doi = {10.1111/1756-185x.70303}
}
Kostenlos starten →